Pay in 4 interest-free payments of $6.44 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
In animal studies, no observable adverse effects were reported, and the compound did not affect food intake or inhibit related enzymes
Preclinical work has shown that cagrilintides weight-lowering effects are mediated primarily via AMY1 and AMY3 receptor subtypes, which are highly expressed in appetite-regulating regions of the brain
Up-regulation of EGR-1 and cyclin D1 A bit more technical: EGR-1 (Early Growth Response 1) and cyclin D1 are transcription factors, proteins that, in the cells nucleus, determine which genes are switched on
The REDEFINE 1 trial found that when evaluating the treatment effect regardless of whether patients stayed on treatment, those treated with CagriSema achieved weight loss of 20.4% (from an average baseline body weight of 236 lb) at 68 weeks versus 3.0% (from an average baseline body weight of 235 lb) for the placebo group which was statistically significant
US$ 20.80
US$ 24.81
US$ 21.18
US$ 20.40
US$ 21.14
US$ 24.25
